MAHLY (Medipal Holdings) EBIT: $540 Mil (TTM As of Mar. 2026)


MAHLY Medipal Holdings Corp MAHLY
78 GF Score
Price $15.37
GF Value $16.06
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Medipal Holdings EBIT?

Medipal Holdings MAHLY 78 EBIT is $540 Mil as of Mar. 2026. GuruFocus rates MAHLY with a GF Score™ of 78/100 and a GF Value™ of $16.06 (Fairly Valued). The stock has 1 warning sign investors should review.

Medipal Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $96 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $540 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medipal Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was 3.03%. Medipal Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 22.34%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medipal Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 24.18%.


Medipal Holdings  (OTCPK:MAHLY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medipal Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=252.024 * ( 1 - 51.95% )/( (4017.939 + 3977.761)/ 2 )
=121.097532/3997.85
=3.03 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12951.743 - 7164.423 - ( 1769.381 - max(0, 7544.175 - 9425.219+1769.381))
=4017.939

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12112.234 - 6312.768 - ( 1821.705 - max(0, 6730.671 - 8640.041+1821.705))
=3977.761

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Medipal Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=384.92/( ( (1684.937 + max(111.663, 0)) + (1650.066 + max(-352.168, 0)) )/ 2 )
=384.92/( ( 1796.6 + 1650.066 )/ 2 )
=384.92/1723.333
=22.34 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5658.711 + 1407.523 + 589.604) - (7164.423 + 0 + 379.752)
=111.663

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5090.965 + 1199.854 + 87.683999999999) - (6312.768 + 0 + 417.903)
=-352.168

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medipal Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=540.162/2234.019
=24.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medipal Holdings EBIT Related Terms


Medipal Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Medipal Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medipal Holdings EBIT Chart

Medipal Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 483.23 524.41 498.93 514.84 515.85

Medipal Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.41 129.21 143.01 171.71 96.23

MAHLY vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, Medipal Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medipal Holdings EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medipal Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medipal Holdings's EV-to-EBIT falls into.


MAHLY
78GF Score
Medipal Holdings Corp MAHLY
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medipal Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $540 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $540 Mil mean?
Medipal Holdings (MAHLY) has a EBIT of $540 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medipal Holdings.
Is Medipal Holdings' EBIT too high?
Medipal Holdings' current EBIT is $540 Mil. Overall, Medipal Holdings has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' EBIT compare to MCK and COR?
Medipal Holdings' EBIT of $540 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medipal Holdings. Medipal Holdings's current EBIT is $540 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MAHLY) is currently considered Fairly Valued. The stock's GF Value™ is $16.06, compared to a current price of $15.37 — trading 4.3% below its estimated fair value. The current EBIT is $540 Mil. Medipal Holdings' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medipal Holdings (MAHLY), the current EBIT is $540 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medipal Holdings (MAHLY) Overvalued in 2026?

Based on GuruFocus' analysis, Medipal Holdings stock appears to be undervalued. The current stock price of $15.37 is trading 4.3% below its estimated GF Value™ of $16.06. GuruFocus considers Medipal Holdings to be Fairly Valued.

Key valuation signals for MAHLY:

  • EBIT: $540 Mil
  • GF Value™: $16.06 vs. price of $15.37 (4.3% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the MAHLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medipal Holdings Business Description

Other Exchanges MEPDF:USA7459:Japan
Address 3-1-1 Kyobashi, Chuo-ku, Tokyo, JPN, 104-8461
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
78GF Score

Get the complete analysis for MAHLY

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.37
Price
$16.06
GF Value